Lymph node metastasis (LNM) critically determines recurrence and survival in cervical cancer (CC), yet current imaging-based methods lack accuracy.
Retroperitoneal lymph node dissection leads to many adverse events.
This study aimed to develop a clinically actionable molecular signature to predict LNM, enabling personalized surgical planning and improved patient outcomes.
